Wayfenac-SP Tablet is a combination analgesic formulation containing Diclofenac 50 mg, Paracetamol 325 mg, and Serratiopeptidase 10 mg, designed to provide effective relief from pain and inflammation. Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), exerts its effect by inhibiting cyclooxygenase enzymes, thereby reducing the synthesis of prostaglandins responsible for inflammation and pain. Paracetamol acts centrally to alleviate pain and reduce fever through inhibition of prostaglandin synthesis in the central nervous system. Serratiopeptidase, a proteolytic enzyme, facilitates the breakdown of inflammatory mediators and promotes the resolution of edema and swelling. The synergistic action of these three components makes Wayfenac-SP effective in managing acute musculoskeletal pain, post-operative pain, dental pain, and inflammatory conditions such as arthritis. This combination is particularly beneficial in reducing pain intensity and improving patient mobility while minimizing the need for higher doses of individual agents, thereby potentially reducing adverse effects. Wayfenac-SP should be used under medical supervision, with caution advised in patients with gastrointestinal ulcers, hepatic or renal impairment, and hypersensitivity to NSAIDs or paracetamol. It is contraindicated in patients with known allergy to any component and should be avoided during pregnancy and lactation unless prescribed by a healthcare professional.